Oppenheimer Raises Price Target on Medtronic (MDT) to $94 Following EPS Beat
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Oppenheimer reiterated an Outperform rating on Medtronic, Inc. (NYSE: MDT), and raised the price target to $94.00 (from $90.00), following the company's 1Q earnings report. MDT reported a $0.02 EPS beat, driven by a slightly lower interest expense and tax rate.
Analyst Steven Lichtman commented, "MDT delivered an in-line F1Q operationally with EPS coming in $0.02 ahead on slightly lower interest expense and tax rate. The underlying story remained the same as new product launches, emerging market expansion and hospital service offerings drove ~5%/15% constant currency constant week (CCCW) sales/EPS growth in F1Q. MDT reiterated FY17 guidance, including 5-6% CCCW sales growth and EPS of $4.60-$4.70 (12-16% CCCW). Covidien synergies are on target, and free cash flow is on track to accelerate to $6.5-7.0B in FY17. We continue to see cash flow flexibility providing upside opportunities ahead in the form of accelerated buybacks, solid dividend growth and tuck-in M&A (including the recent Heartware acquisition). MDT’s scale is another key positive in today's environment."
Shares of Medtronic, Inc. closed at $85.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Remains Sidelined on Crane Co. (CR) Following Earnings Call
- New Oriental Education (EDU) PT Raised to $60 at Brean Capital
- Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesEarnings, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!